Neurocrine Biosciences’ Post

Early detection of #ATTR allows for improved patient outcomes, which is why it’s so important to explore novel biomarkers of disease progression and treatment response.

🚀I’m pleased to share my recently published article titled "MicroRNA Biosensors for Detection of Chronic Kidney Disease," featured in @#Clinica Chimica Acta.In this review, we explore the innovative use of microRNA (miRNA) biosensors as non-invasive diagnostic tools for chronic kidney disease (CKD). Our findings highlight the potential of these biosensors to detect specific miRNAs associated with CKD, which can significantly enhance early diagnosis and patient management. By discussing various biosensor technologies, including electrochemical and optical methods, we aim to shed light on their advantages, limitations, and future applications in clinical settings.I would like to thank my co-authors #ahmad movahedpour and other collaborators for their invaluable contributions to this work. You can read the full article here: #MicroRNA Biosensors for Detection of Chronic Kidney Disease.

Promising #ctDNA study to help understand risk of recurrence in #TNBC and #BRCA-positive early #breastcancer ends due to low enrollment. This discontinued study reported at #SABCS24 suggests potential for liquid biopsy to guide treatment and offers takeaways for future research. Learn more https://bit.ly/4giDJIz #ctDNA #SABCS24 #breastcancer

Pathogenic transthyretin aggregates may be a future target for diagnosis and treatment of ATTR amyloidosis. This promissing study of Rose Pedretti designed a probe (TAD) for the detection of pathogenic TTR aggregates. The study identified agregates in ATTR patients and showed a reduction post treatment. #amyloidosis #cardiacamyloidosis #ATTR

Researchers used our Nutragen® (6mg/ml collagen) for a "3D Fibroblast Collagen Contraction Assay." This was part of a study to better understand the role of RUNX1 in the fibrotic progression of the autoimmune disease Systemic Sclerosis. Dermal fibrosis is a clinical manifestation of Systemic Sclerosis, resulting from the uncontrolled deposition of extracellular matrix. This study is the first to demonstrate a potential role for RUNX1 in the pathogenesis of Systemic Sclerosis Dermal Fibrosis. Read the full publication here: https://lnkd.in/e8pCyNkk #cellculture #collagen #3D

Metformin What about for PVR Should patient with RRD at risk be put on metformin ? AMD with a subretinal bleed 🩸? Study findings A study found that metformin can prevent TGF-β from causing hand fibroblasts to differentiate into myofibroblasts. It also inhibited the expression of fibrotic markers and contraction in hand-derived fibroblasts. It works for fibrosis reduction

Check out this week’s fresh group of fascinating articles. Firstly, scientists at University of Texas Medical Branch have recently announced a new method for treating against neurodegenerative conditions like Alzheimer’s disease. It involves a nasal spray that has demonstrated effectiveness in eliminating harmful tau protein accumulation. https://lnkd.in/gfSkinxJ? Secondly, scientists have discovered a treatment involving the blood-thinning drug heparin, which may help reduce the risk of tissue death from a cobra’s venom, which can lead to amputations. https://lnkd.in/gzT3mS9t Thirdly, a drug that inhibits inflammation helped mice live longer and reduced the animals’ incidence of cancer and age-related health problems. https://lnkd.in/gUKxk2hz #manhattanlife #medicalscienceandtech #medicaltechnology #healthscience

Evaluating Prognostic Indicators in Acute PE with Malignancy This study examines how the Eastern Cooperative Oncology Group Performance Status (ECOG PS) impacts short- and long-term mortality in acute pulmonary embolism (PE) patients with advanced malignancies, in correlation with the simplified Pulmonary Embolism Severity Index (sPESI). Findings indicate that patients with an ECOG PS ≥ 3 exhibit poorer survival outcomes, highlighting the need for tailored care strategies for those with concurrent malignancy and acute PE. Read more: https://hubs.la/Q02WBDSj0 #PulmonaryEmbolism #OncologyResearch #ECOG #CancerPatients #Thrombosis #MortalityRisk #ECOGScore #KamedaMedicalCenter #PrognosticIndicators #ClinicalOutcomes #CureusJournal #sPESI #CancerCare #PatientSurvival #MedicalResearch

Evaluating Prognostic Indicators in Acute PE with Malignancy This study examines how the Eastern Cooperative Oncology Group Performance Status (ECOG PS) impacts short- and long-term mortality in acute pulmonary embolism (PE) patients with advanced malignancies, in correlation with the simplified Pulmonary Embolism Severity Index (sPESI). Findings indicate that patients with an ECOG PS ≥ 3 exhibit poorer survival outcomes, highlighting the need for tailored care strategies for those with concurrent malignancy and acute PE. Read more: https://hubs.la/Q02WBzHz0 #PulmonaryEmbolism #OncologyResearch #ECOG #CancerPatients #Thrombosis #MortalityRisk #ECOGScore #KamedaMedicalCenter #PrognosticIndicators #ClinicalOutcomes #CureusJournal #sPESI #CancerCare #PatientSurvival #MedicalResearch

Evaluating Prognostic Indicators in Acute PE with Malignancy This study examines how the Eastern Cooperative Oncology Group Performance Status (ECOG PS) impacts short- and long-term mortality in acute pulmonary embolism (PE) patients with advanced malignancies, in correlation with the simplified Pulmonary Embolism Severity Index (sPESI). Findings indicate that patients with an ECOG PS ≥ 3 exhibit poorer survival outcomes, highlighting the need for tailored care strategies for those with concurrent malignancy and acute PE. Read More: https://hubs.la/Q02XD9-P0 #PulmonaryEmbolism #OncologyResearch #ECOG #CancerPatients #Thrombosis #MortalityRisk #ECOGScore #KamedaMedicalCenter #PrognosticIndicators #ClinicalOutcomes #CureusJournal #sPESI #CancerCare #PatientSurvival #MedicalResearch